A class of drugs developed to treat immune-related conditions and cancer
-- including one currently in clinical trials for glioblastoma and
other tumors -- eliminates neural inflammation associated with
dementia-linked diseases and brain injuries, according to researchers.
In their study, the researchers discovered that the drugs, which can be
delivered orally, eradicated microglia, the primary immune cells of the
brain. These cells exacerbate many neural diseases, including
Alzheimer's and Parkinson's, as well as brain injury.
-- including one currently in clinical trials for glioblastoma and
other tumors -- eliminates neural inflammation associated with
dementia-linked diseases and brain injuries, according to researchers.
In their study, the researchers discovered that the drugs, which can be
delivered orally, eradicated microglia, the primary immune cells of the
brain. These cells exacerbate many neural diseases, including
Alzheimer's and Parkinson's, as well as brain injury.
No comments:
Post a Comment